Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68033 | 1.00 | MMP13 (0.38) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL30884895 | 0.88 | MMP13 (0.32) | MMP13MEN1GAAKMT2AHDAC6 | |
| SCHEMBL18248156 | 0.88 | MMP13 (0.38) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL20586574 | 0.88 | MMP13 (0.38) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL18248003 | 0.86 | MMP13 (0.37) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL18248197 | 0.86 | MMP13 (0.37) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL28815034 | 0.86 | MMP13 (0.37) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL18248032 | 0.86 | MMP13 (0.37) | MMP13AAK1MEN1GAAKMT2A | |
| SCHEMBL21447929 | 0.86 | MMP13 (0.37) | MMP13AAK1HDAC6HDAC1HDAC2 | |
| SCHEMBL18248055 | 0.86 | MMP13 (0.37) | MMP13AAK1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114891070-A | Anthelmintic depsipeptide compounds | 勃林格殷格翰动物保健美国公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-107835818-B | Anthelmintic depsipeptide compounds | 勃林格殷格翰动物保健美国公司 | 2022-04-29 | — | — | CN | disclosed |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20180362589-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2018-12-20 | — | — | US | disclosed |
| CN-107835818-A | Anthelmintic depsipeptide compounds | 梅里亚股份有限公司 | 2018-03-23 | — | — | CN | disclosed |
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | disclosed |
| CN-102292319-A | Novel substituted octahydrocyclopenta(C)pyrrol-4-amines as calcium channel blockers | — | 2011-12-21 | — | — | CN | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2367790-A2 | SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010062927-A2 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | MMP13 4411/4885AAK1 1519/4885MEN1 1286/4885 |
| US-20180362589-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | MMP13 504/4885AAK1 3412/4885MEN1 1902/4885 |
| US-10793604-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | MMP13 504/4885AAK1 3412/4885MEN1 1902/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | MMP13 4411/4885AAK1 1519/4885MEN1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.